Edesa Biotech Inc (EDSA) News & EventsEDSANews & EventsEdesa Biotech Inc

Edesa Biotech Commences Underwritten Public Offering of Common Shares

Edesa Biotech announced that it has commenced an underwritten public offering of its common shares and accompanying common share warrants to purchase common shares. All common shares, pre-funded warrants and accompanying common share warrants are being offered by Edesa. Edesa intends to use the net proceeds from the proposed offering for general corporate purposes, which may include working capital, capital expenditures and research and development and manufacturing expenses. Guggenheim Securities is acting as the sole book-running manager for the proposed offering.

Edesa Biotech Files to Sell 729,241 Common Shares

Edesa Biotech files to sell 729,241 common shares for holders

Edesa Biotech Enters Securities Purchase Agreement for $3.5M Financing

Edesa Biotech announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $3.5M to the company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa's CEO and healthcare-focused investors. The PIPE is expected to close on or about June 15, subject to the satisfaction of customary closing conditions. In the PIPE, the company is selling an aggregate of 729,241 common shares, at a purchase price of $4.69 per common share for investors and $5.21 per common share for Edesa's CEO.